ECPC Logo 4C K W September 1

 

PERSONALISED MEDICINE AWARENESS MONTH - NOVEMBER 2018

Too many people diagnosed with cancer do not have access to the personalised treatment they need and deserve. This can be due to a lack of awareness and education amongst patients and healthcare professionals, or a variety of access challenges such as pricing, reimbursement or limited availability. This needs to change.

In 2018, throughout the month of November, the European Cancer Patient Coalition will promote the importance of access to cancer molecular testing during a month-long advocacy campaign, Personalised Medicine Awareness Month: Cracking the Cancer Code.

The European Cancer Patient Coalition and our member organisations believe that people living with cancer should be informed about all available treatment options and be empowered to make the best decisions for their health together with their healthcare team. That’s why ECPC is working towards ensuring all Europeans with cancer and at risk of getting cancer to have appropriate access to cancer molecular testing. This will help to promote better diagnosis, more targeted follow up and a truly personalised treatment.

During Personalised Medicine Awareness Month 2018, the European Cancer Patient Coalition and its members will unite to call for:

  • Increased access and decreased waiting times for high-quality molecular testing to make personalised healthcare more of a reality across Europe;
  • More information to educate and empower patients and caregivers around the potential and availability of molecular testing;
  • A harmonised and more efficient regulatory framework across Europe which could increase access to, and potentially reduce the cost of, molecular testing. 

 


 
How will the campaign evolve?

The European Cancer Patient Coalition and its members will be provided with a digital toolkit to advocate both at the National and at the European level. The toolkit will be a complete and effective advocacy instrument as it will inform our members on the importance of molecular testing and provide them with template letters to reach out to their local representatives with their demands. Social media material such as visuals and accompanying texts will also be provided. In this way, thousands of patients all across Europe will be empowered to get the personalised medicine they deserve. 

In the coming weeks, refer to this webpage to receive updates on the campaign. 

If you want to get involved, please fill in the google form at this link and we will get back to you.

 

The European Cancer Patient Coalition gratefully acknowledges the support of AbbVie, AstraZeneca, Bristol-Myers SquibbCancer Drug Development Forum, Genomic Health, Johnson & Johnson, Merck, MSD, Roche, Takeda.


 abbvie               astrazeneca             bms
 
CDDF LOGO          genomichealth          jj             merck 

 

                                                  msd              roche                  takeda